FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products
September 24, 2023FDA Approves Likmez (metronidazole) Oral Suspension for the Treatment of Parasitic and Anaerobic Bacterial Infections
September 25, 2023Upcoming Formulary Changes
BeneCard PBF is committed to providing innovative clinical solutions, valuable trend management strategies, and the highest quality of service. We regularly conduct a review of our formulary to remain current with the ever‐changing prescription drug landscape.
During this review process, we consider changes that occur with new FDA approvals (brand and generic) and the latest clinical information. This comprehensive review looks at each therapeutic category to identify clinically superior products at the lowest net cost. This process is essential to help control pharmaceutical spend as drug costs, particularly for already costly specialty medications, increase over time. Our goal when considering updates to our formularies is to improve member health outcomes while maximizing plan savings.
December 2023 Changes
The following changes to the Primary Formulary will go into effect on December 1, 2023.
| Moved from Non‐Preferred to Preferred | Most Common Indication/Use |
|---|---|
| LUPRON DEPOT‐PED 45MG | Central Precocious Puberty |
January 2024 Changes
The following changes to the Primary Formulary will go into effect on January 1, 2024.
| Adding as Preferred on Launch* | Most Common Indication/Use |
|---|---|
| PAXLOVID TAB 150‐100MG & 300‐100MG | COVID‐19 |
| Moved from Non‐Preferred to Preferred | Most Common Indication/Use |
|---|---|
| LUPRON DEPOT‐PED 45MG | Central Precocious Puberty |
| MEKINIST ORAL SOLUTION | BRAF Mutation‐Positive Cancers |
| TAFINLAR 10MG TABLET | BRAF Mutation‐Positive Cancers |
| LO LOESTRIN FE | Contraception |
| AUVI‐Q | Anaphylaxis |
| TEZSPIRE AUTO‐INJECTOR | Severe Asthma |
| ONETOUCH/LIFESCAN TEST STRIPS | Diabetic Supplies |
| ONETOUCH/LIFESCAN CALIBRATION SOLN | Diabetic Supplies |
| LIFESCAN BLOOD GLUCOSE METERS/KITS | Diabetic Supplies |
| Moved from Preferred to Non‐Preferred | Most Common Indication/Use |
|---|---|
| FLOVENT DISKUS | Asthma |
| FLOVENT HFA | Asthma |